A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia-Reference-Cited by-同舟云学术

A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia

Published:2020-01-08 Issue:7 Volume:29 Page:796-802
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Dormuth Colin R.¹^ORCID,Fisher Anat¹^ORCID,Carney Greg¹^ORCID

Affiliation:

1. Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Vancouver British Columbia Canada

Funder

Pharmaceutical Service Division, Ministry of Health, Government of British Columbia

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4957

Reference15 articles.

1. British Columbia Ministry of Health[Internet]. Biosimilars Initiative for patients. Available from:https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/biosimilars-initiative-patientsAccessed May 31 2019.

2. British Columbia Ministry of Health[Internet]. Reference Drug Program (RDP). Available from:https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/reference-drug-program. Accessed May 31 2019.

3. Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors

4. Impact of reference‐based pricing for angiotensin‐converting enzyme inhibitors on drug utilization;Schneeweiss S;CMAJ,2002

5. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study;Gastroenterology Research and Practice;2023-03-01

2. The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine;Clinical Therapeutics;2022-07

3. Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia;BMC Rheumatology;2022-01-27

4. Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study;CMAJ Open;2022-01

5. Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report;Pharmacoepidemiology and Drug Safety;2020-05-28